.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,113,906

« Back to Dashboard

Claims for Patent: 6,113,906

Title: Water-soluble non-antigenic polymer linkable to biologically active material
Abstract:Branched, substantially non-antigenic polymers are disclosed. Conjugates prepared with the polymers and biologically active molecules such as proteins and peptides demonstrate extended circulating life in vivo. Substantially fewer sites on the biologically active material are used as attachment sites. Methods of forming the polymer, conjugating the polymers with biologically active moieties and methods of using the conjugates are also disclosed.
Inventor(s): Greenwald; Richard B. (Somerset, NJ), Martinez; Anthony J. (Hamilton Square, NJ)
Assignee: Enzon, Inc. (Piscataway, NJ)
Application Number:09/222,463
Patent Claims: 1. A substantially non-antigenic polymer of the formula: ##STR33##

2. A substantially non-antigenic polymer of the formula: wherein (A) is a functional group capable of bonding with a biologically active nucleophile, or a spacer moiety capable of being functionalized to react with a biologically active nucleophile.

3. A substantially non-antigenic polymer of the formula: ##STR34## wherein (A) is a functional group of a biologically active material

capable of reacting with an amino group.

4. A substantially non-antigenic polymer conjugate of the formula: ##STR35## wherein (A') is a linkage moiety.

5. A branched substantially non-antigenic polymer of the formula:

wherein:

(R) is a monomethyl polyethylene glycol;

(n) is 2;

(A) is a functional group capable bonding with a biologically active nucleophile, or a spacer moiety capable of being functionalized to react with a biologically active nucleophile ##STR36## wherein each (R) is linked to (L) by a urethane linkage.

6. A polymeric conjugate of the formula:

wherein:

(R) is a monomethyl polyethylene glycol;

(n) is 2; ##STR37## wherein each (R) is linked to (L) by a urethane linkage, (A') represents a linkage between (L) and the biologically active nucleophile;

(z) is an integer .ltoreq.1; and

(nucleophile) is a biologically active nucleophile.

7. The polymeric conjugate of claim 6, wherein the (nucleophile) is .alpha.-interferon and (z) is one.

8. A substantially non-antigenic polymer conjugate of the formula: ##STR38##

9. The conjugate of claim 8, wherein said protein is an interferon.

10. The polymer conjugate of claim 9, wherein said interferon is an .alpha.-interferon.

11. A substantially non-antigenic polymer conjugate of the formula: wherein each (R) is a water-soluble substantially non-antigenic polymer containing a C.sub.1-4 terminal group, each (R) is linked to each NH via a urethane bond and the polymer portion thereof has a molecular weight of less than about 80,000 Daltons.

12. The conjugate of claim 11, wherein said protein is an interferon.

13. The polymer conjugate of claim 12, wherein said interferon is an .alpha.-interferon.

14. The conjugate of claim 11, wherein each (R) is a polyalkylene oxide.

15. The conjugate of claim 14, wherein said polyalkylene oxide is polyethylene glycol.

16. The conjugate of claim 15, wherein said polyalkylene oxide is monomethoxypolyethylene glycol.

17. The substantially non-antigenic polymer of claim 1, wherein the molecular weight of said polymer is less than about 80,000 Daltons.

18. The substantially non-antigenic polymer conjugate of claim 4, wherein the molecular weight of the polymer portion thereof is less than about 80,000 Daltons.

19. The substantially non-antigenic polymer conjugate of claim 8, wherein the molecular weight of the polymer portion thereof is less than about 80,000 Daltons.

20. The substantially non-antigenic polymer conjugate of claim 11, wherein the molecular weight of the polymer portion thereof is less than about 80,000 Daltons.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc